Group 1: Core Insights - The article discusses the financing status and trends in the biomedical materials industry in China from 2020 to 2025, highlighting significant investment events and the overall investment landscape [1][5][19]. Group 2: Financing Events Summary - A summary of major financing events in the biomedical materials industry from 2020 to 2025 is provided, detailing various companies, funding rounds, amounts, and investors [2][3][4]. - Notable financing events include: - Xintai Medical received 129.78 million RMB in strategic investment on June 23, 2025 [2]. - SupiraMedical raised 40 million USD in a D round on November 22, 2023 [3]. - Multiple companies, such as MoDi Bio and Rongmai Medical, have engaged in various funding rounds, indicating a vibrant investment environment [2][3][4]. Group 3: Financing Scale Analysis - The financing scale in the biomedical materials manufacturing industry shows a trend of "initial rise, peak, and subsequent adjustment," with financing occurrences peaking at 13 in 2021 and dropping to 4 in the first half of 2025 [5]. - The total financing amount reached a peak of 5.473 billion RMB in 2021, followed by a significant decline to 201 million RMB in the first half of 2025 [5]. Group 4: Financing Rounds Analysis - Since 2020, early-stage financing rounds have dominated, with A rounds being the most active at 15 occurrences, followed by angel rounds at 9 [7]. - Early-stage rounds (angel, Pre-A, A, and A+ rounds) accounted for over 60% of total financing events, indicating a preference for investing in early-stage companies [7]. Group 5: External Investment Landscape - The primary regions for external investments by major biomedical materials companies in China are Beijing and Shanghai, with 30 and 25 investments, respectively [10]. - The industry investment layout shows that scientific research and technical services account for 42%, manufacturing for 23%, and wholesale and retail for another 23% [11]. Group 6: Mergers and Acquisitions - The mergers and acquisitions market in the biomedical materials sector is characterized by continuous growth, with horizontal mergers being the primary focus, supported by policy incentives and industry demands [12]. - Recent notable transactions include: - SINOCERA's acquisition of DEKEMA for 10.21 million RMB, enhancing its product layout in the dental field [15]. - The acquisition of SPIDENT by SINOCERA for 704 million RMB, aimed at expanding its presence in the dental medical field [15]

FF301 第 1 頁 共 11 頁 v 1.1.1 備註： 2. 股份分類 普通股 股份類別 A 於香港聯交所上市 (註1) 否 證券代號 (如上市) N/A 說明 A股（上海證券交易所科創板，股份代號：688366） 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 194,051,855 RMB 1 RMB 194,051,855 增加 / 減少 (-) 0 RMB 0 本月底結存 194,051,855 RMB 1 RMB 194,051,855 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 06826 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 38,529,240 RMB 1 RMB 38,529,240 增加 / 減少 (-) 0 RMB 0 本月底結存 38,529,240 RMB 1 RMB 38,529,240 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 截至月份: 2025年9月30日 狀態: 新提交 本月 ...

致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 11 頁 v 1.1.1 備註： 2. 股份分類 普通股 股份類別 A 於香港聯交所上市 (註1) 否 證券代號 (如上市) N/A 說明 A股（上海證券交易所科創板，股份代號：688366） 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 194,051,855 RMB 1 RMB 194,051,855 增加 / 減少 (-) 0 RMB 0 本月底結存 194,051,855 RMB 1 RMB 194,051,855 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 06826 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 38,529,240 RMB 1 RMB 38,529,240 增加 / 減少 (-) 0 RMB 0 本月底結存 38,529,240 RMB 1 RMB 38,529,240 ...

Core Viewpoint - The company announced a share reduction plan by a major shareholder, which involves the potential sale of up to 1.5 million shares, representing approximately 0.6432% of the total share capital [1] Group 1: Shareholder Reduction Plan - The shareholder, Mr. Lou Guoliang, plans to reduce his holdings through both centralized bidding and block trading methods within three months following the announcement [1] - The maximum number of shares to be reduced is 1.5 million, with the reduction price determined by the secondary market [1] - As of September 29, 2025, Mr. Lou has successfully reduced his holdings by 1.4914 million shares, which is about 0.6413% of the company's total share capital [1]

Core Viewpoint - Haohai Biological Technology announced a share reduction plan by shareholder Mr. Lou Guoliang due to personal financial needs, intending to reduce up to 1.5 million shares, representing no more than 0.6432% of the company's total share capital of 233 million shares [1] Summary by Sections - **Share Reduction Plan** - Mr. Lou Guoliang plans to reduce his holdings through centralized bidding and block trading, with a total reduction not exceeding 1.5 million shares [1] - The reduction will occur within three months after the announcement date, starting from three trading days post-announcement [1] - **Reduction Details** - The maximum reduction through centralized bidding is capped at 1.5 million shares, with the same limit for block trading [1] - The reduction price will be determined based on the secondary market price [1] - **Reduction Outcome** - As of September 29, 2025, Mr. Lou Guoliang has reduced his holdings by 1.4914 million shares through centralized bidding, which is approximately 0.6413% of the current total share capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年9月29日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号：2025-043 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司股 東減持股份結果公告》， ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-043 减持计划的实施结果情况 公司于 2025 年 6 月 25 日披露了《上海昊海生物科技股份有限公司股东减持 股份计划公告》（公告编号：2025-032），楼国梁先生因自身资金需要，计划自该 公告披露之日起 3 个交易日后 3 个月内，通过集中竞价和大宗交易方式合计减持 不超过 1,500,000 股的公司股份，占减持计划披露时公司总股本 233,193,695 股的 比例不超过 0.6432%，其中，通过集中竞价方式减持不超过 1,500,000 股，通过 大宗交易方式减持不超过 1,500,000 股。减持价格将根据二级市场价格确定。 公司于 2025 年 9 月 29 日收到楼国梁先生出具的《关于股份减持结果的告知 函》，其本次股份减持计划时间区间届满。截至 2025 年 9 月 29 日，楼国梁先生 已通过集中竞价的方式累计减持公司股份 1,491,447 股，占目前公司总股本 232,581,095 股的 0.6413%。现将具体情况公告如下： 1 上海昊海生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股 ...

Core Viewpoint - Haohai Biological Technology (688366.SH) announced the completion of a share reduction plan by Mr. Lou Guoliang, who has reduced his holdings in the company [1] Summary by Relevant Sections - Share Reduction Details - Mr. Lou Guoliang has reduced his shareholding by a total of 1.4914 million shares, which accounts for 0.6413% of the company's total share capital as of September 29, 2025 [1]

Group 1 - The 2025 World Design Capital Conference (WDCC2025) opened on September 25 in Shanghai, showcasing nearly 500 participating brands and over 3,000 exhibits within an exhibition space of approximately 15,000 square meters, with international brands accounting for about 20% and emerging brands for about 60% [1] - The MG brand, known for its sporty DNA and unique design, presented electric sports cars inspired by racing helmets, embodying a blend of speed, passion, and youthfulness, and aims to transform into a "mobile trendy toy" that is interactive and relatable [4][3] - The MANITO OASIS installation, created by the Canadian silk brand MANITO, emphasizes a nature-inspired design, capturing the beauty of the natural world and promoting the brand's philosophy of a natural lifestyle [6][5] Group 2 - The Shanghai-based medical company Haohai Biological Technology showcased an immersive art exhibition titled "Renaissance of Cells," breaking traditional display methods and allowing audiences to experience a molecular network beyond human scale, highlighting the revival of cells [8][7] - The installation features a giant transparent sphere connected by fine metal rods, resembling a molecular framework, and transforms laboratory scenes into an artistic representation of a dynamic life theater, enabling viewers to glimpse the universe from a microscopic perspective [8]

FF305 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年9月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括 ...